Form 4: Acadia Pharmaceuticals CEO Stephen Davis Reports Stock Transactions
SEC Form 4 Filing
Acadia Pharmaceuticals CEO Stephen Davis reports the acquisition of 10,946 shares of common stock through restricted stock unit vesting and the sale of 5,577 shares to cover withholding taxes.
Summary
- On February 23, 2024, Stephen Davis, CEO of Acadia Pharmaceuticals, acquired 10,946 shares of common stock due to the vesting of restricted stock units.
- On February 26, 2024, Davis sold 5,577 shares at a price of $24.67 per share.
- The sale was conducted to cover withholding taxes and tax-related items associated with the vesting of the restricted stock units.
- Following these transactions, Davis directly owns 101,890 shares of Acadia Pharmaceuticals common stock.
- Davis also directly owns 10,946 restricted stock units.
Sentiment
Score: 5
Explanation: The document reflects routine insider transactions (stock vesting and sales for tax purposes), indicating a neutral sentiment.
Positives
- The vesting of restricted stock units indicates a form of compensation and alignment of interests between the CEO and the company's performance.
Negatives
- The sale of shares by the CEO, even to cover taxes, could be perceived negatively by some investors, although it's a common practice.
Risks
- While the sale of shares to cover taxes is routine, significant or frequent sales by executives could signal concerns about the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance.
Industry Context
Insider transactions are closely monitored in the pharmaceutical industry to gauge executive confidence and potential future performance. These transactions are a normal part of executive compensation.
Comparison to Industry Standards
- Stock sales to cover taxes on vesting equity are common among executives in publicly traded companies, including those in the pharmaceutical sector.
- Comparing Davis's transactions to those of executives at similar-sized pharmaceutical companies like Neurocrine Biosciences or Biohaven Pharmaceuticals would provide a better benchmark.
Stakeholder Impact
- The transactions may have a minor impact on shareholders' perception of the company, but are generally considered routine.
Key Dates
| Date | Description |
|---|---|
| February 6, 2024 | Date of Power of Attorney execution. |
| February 23, 2022 | Start date for the vesting of restricted stock units in four equal annual installments. |
| February 23, 2024 | Date of acquisition of 10,946 shares of common stock through restricted stock unit vesting. |
| February 26, 2024 | Date of sale of 5,577 shares at $24.67 per share. |
| February 27, 2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.